16
Participants
Start Date
June 30, 2012
Primary Completion Date
June 30, 2013
Study Completion Date
June 30, 2013
JX-594 recombinant vaccina GM-CSF
Enrolled patients will receive 5 weekly IV infusions on Days 1, 8, 15, 22, and 29. After Day 43, if their disease has improved or remained stable and they have not started other cancer therapy, they may be able to continue to receive JX-594 via IV infusion every three weeks. This treatment extension may continue until radiologic progressive disease, initiation of other cancer therapy, or patient withdrawal.
University of Texas Health Science Center at San Antonio, San Antonio
Mayo Clinic, Scottsdale
Pusan National University Hospital, Pusan
Pusan National University Yangsan Hospital, Yangsan
University Clinic of Navarra, Pamplona
Lead Sponsor
Jennerex Biotherapeutics
INDUSTRY